A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD

This study is a multicenter, prospective cohort study designed to enroll 50 NMOSD patients who receive Satralizumab treatment during the early phase of an NMOSD attack. Follow-up visits will be conducted at baseline, 3 months, and 6 months to record and assess EDSS scores, modified Rankin Scale (mRS) scores, EQ-5D scores, Activities of Daily Living (ADL) scores, relapse events, safety data, and exploratory endpoints (e.g., blood inflammatory markers and visual function), with the aim of evaluating the efficacy and safety of Satralizumab in the early treatment of NMOSD-thereby providing patients with more effective therapeutic options and further optimizing the clinical management of NMOSD.

NCT Number	NCT07762872
Lead Sponsor	Junwei Hao, MD Collaborators: The First Hospital of Hebei Medical University, The Second Hospital of Hebei Medical University, First Affiliated Hospital of Harbin Medical University, Shandong Provincial Hospital, Chifeng Municipal Hospital
Conditions	Neuromyelitis Optica Spectrum Disorders (NMOSD)
Enrollment	50 participants
Start Date	2026-07-20
Primary Completion	2027-07-20 (estimated)
Study Completion	2028-01-20 (estimated)
Updated on ClinicalTrials.gov	2026-08-13